key: cord-0693017-rea8z7vc
authors: Liu, Xiaofan; Zhou, Hong; Zhou, Yilu; Wu, Xiaojun; Zhao, Yang; Lu, Yang; Tan, Weijun; Yuan, Mingli; Ding, Xuhong; Zou, Jinjing; Li, Ruiyun; Liu, Hailing; Ewing, Rob M.; Hu, Yi; Nie, Hanxiang; Wang, Yihua
title: Risk Factors Associated with Disease Severity and Length of Hospital Stay in COVID-19 Patients
date: 2020-04-17
journal: J Infect
DOI: 10.1016/j.jinf.2020.04.008
sha: 075d097dc8d8c4a03403fb05093adbfda36699f3
doc_id: 693017
cord_uid: rea8z7vc

nan

We read with interest the article in this journal which revealed the critical role of timely supply of medical resources for COVID-19 patients (1). The pandemic of COVID-19 has placed an enormous burden on health authorities across the world. The virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously known as 2019-nCoV), causes acute respiratory disease with common signs of infection being respiratory symptoms, fever, cough and breathing difficulties. In more severe cases, infection causes pneumonia, lung failure, septic shock, organ failure and risk of death. The WHO reports that 80% of those infected will develop mild symptoms, 14% severe symptoms and 6% will become critically ill. Given the wide clinical spectrum of COVID-19, a key challenge faced by frontline clinical staff is prioritisation of stretched resources. Thus, there is a critical need for robust risk assessment for clinical management.

To address this, we identified consecutive patients with moderate or severe COVID-19 discharged from the general wards of Renmin Hospital of Wuhan University between 5 February 2020 to 14 March 2020 (Ethics approval No: WDRY2020-K124). All patients had been diagnosed with COVID-19 according to WHO interim guidance and had radiologic evidence of pneumonia or infiltrates on chest CT scan according. The criteria for patient discharge was the absence of fever for at least 3 days, substantial improvement in both lungs on chest CT, clinical remission of respiratory symptoms, and two throat-swab samples negative for viral RNA obtained at least 24 hours apart. In total, 99 patients (61 pneumonia and 38 severe pneumonia) with key information in their medical records were included in this study. Demographic, clinical, laboratory, and treatment data were extracted from electronic medical records. Risk factors that affect disease severity and length of hospital stay were investigated with appropriate statistical methods using R (V3.6.1) or GraphPad Prism (V8.2.1).

To explore the risk factors associated with disease severity, univariate and multivariate logistic regression models were used. In univariate analysis, hypertension, lymphopenia, elevated neutrophil count, lactate dehydrogenase (LDH), C-reactive protein (CRP), and symptoms such as dyspnea, fatigue, and anorexia/lethargy were all associated with severe cases (Figure 1a ; p < 0.05). In the multivariable logistic regression model, we included 90 patients (56 pneumonia and 34 severe pneumonia) with complete data for those significant variables from univariate analysis.

We identified hypertension (Odds ratio: 3.59; p = 0.048), increased CRP (Odds ratio: 1.38; p = 0.01) and lymphocyte count (Odds ratio: 0.10; p = 0.004) as independent predictors of severe pneumonia (Figure 1b) .

In this cohort, all the patients were discharged. As expected, COVID-19 patients with pneumonia were discharged sooner than those with severe cases (Figure 2a Cytopathic effects and inflammatory response induced by virus as well as viral evasion of host immune responses are thought to play critical roles in disease severity (2, 3) . Consistent with this, we identified increased CRP and lymphopenia as independent risk factors for disease severity, while lymphopenia is also a risk factor for prolonged hospital stay. As a result, we recommend surveillance of CRP and lymphocyte counts in the early screening of critical illness in COVID-19 patients.

It has been confirmed that SARS-CoV2 utilizes angiotensin-converting enzyme 2 (ACE2) as receptor for viral cell entry. Given that ACE2 levels are increased in hypertensive patients treated with ACE inhibitors (ACEIs) and angiotensin II type-I receptor blockers (ARBs) (4, 5), Fang and colleagues proposed the hypothesis that ACE2-stimulating drugs could potentially increase the risk of developing severe and fatal COVID-19 (6) . In this study, we found hypertension is a risk factor for severe cases, independent of age and other variables. We managed to trace 34 hypertensive patients in this cohort. We found 1 out of 14 COVID-19 patients with pneumonia and 4 out of 20 COVID-19 patients with severe pneumonia are on ACEIs/ARBs. The impact of ACEIs/ARBs on disease severity is inconclusive due to small number, but it does suggest a larger cohort study is demanded.

The use of corticosteroids in COVID-19 patients is controversial (7) (8) (9) . The Chinese Thoracic Society has developed an expert consensus statement on the use of corticosteroids in COVID-19 patients (10), in which low-to-moderate dose of corticosteroids in short courses for critically ill COVID-19 patients is recommended. However, there are potential risks associated with corticosteroids, such as secondary infections and prolonged virus shedding (8) . In our study, the log-rank test suggested glucocorticoids use led to a prolonged length of hospital stay in COVID-19 patients, which discourages its use.

There are several limitations in this study. First, not all laboratory examinations were done in all patients due to the retrospective nature of this study. In addition, interpretation of our findings might be limited by the sample size. Despite these limitations, with appropriate statistical tools we are able to identify several risk factors to predict disease severity and length of hospital stay in COVID-19 patients.

Taking together, we report hypertension, increased CRP and lymphopenia as independent risk factors for disease severity. COVID-19 patients with lymphopenia have longer length of hospital stay. In addition, our data do not support corticosteroid treatment for COVID-19 patients. patients with normal or low lymphocyte count (< 1.1 × 10 9 /L). Numbers below are n (%). P-value was calculated by log-rank test. (d) Kaplan-Meier plot showing the overall hospital stay in COVID-19 patients treated with or without glucocorticoids. Numbers below are n (%). P-value was calculated by log-rank test.

Wuhan and Hubei COVID-19 mortality analysis reveals the critical role of timely supply of medical resources. The Journal of infection

COVID-19: consider cytokine storm syndromes and immunosuppression

Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. American journal of hypertension

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory medicine

On the use of corticosteroids for 2019-nCoV pneumonia

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal transduction and targeted therapy

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

We acknowledge all the patients involved in this study, and appreciate all the frontline medical and nursing staff involved in the diagnosis and treatment of patients in Wuhan. We thank Prof Donna E. Davies and Dr Mark G. Jones for critical reading.

None.